HighTower Advisors’s NovoCure NVCR Stock Holding History

HighTower Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,242	Closed	-$256K	–	3605
2023 Q1	$256K	Sell	4,242 -743	-15%	-$59.4K	﹤0.01%	2567
2022 Q4	$364K	Sell	4,985 -802	-14%	-$60.3K	﹤0.01%	2339
2022 Q3	$441K	Sell	5,787 -602	-9%	-$47K	﹤0.01%	2102
2022 Q2	$444K	Sell	6,389 -731	-10%	-$55.1K	﹤0.01%	2121
2022 Q1	$592K	Sell	7,120 -374	-5%	-$27.6K	﹤0.01%	2066
2021 Q4	$565K	Sell	7,494 -68	-0.9%	-$6.83K	﹤0.01%	2073
2021 Q3	$880K	Buy	7,562 +379	+5%	+$57.3K	﹤0.01%	1732
2021 Q2	$1.59M	Sell	7,183 -1,426	-17%	-$277K	﹤0.01%	1365
2021 Q1	$1.14M	Buy	8,609 +617	+8%	+$97.6K	﹤0.01%	1485
2020 Q4	$1.38M	Buy	7,992 +265	+3%	+$36.3K	0.01%	1092
2020 Q3	$860K	Sell	7,727 -1,181	-13%	-$94.4K	﹤0.01%	1289
2020 Q2	$529K	Sell	8,908 -85	-0.9%	-$5.59K	﹤0.01%	1427
2020 Q1	$605K	Buy	8,993 +409	+5%	+$32.3K	﹤0.01%	1253
2019 Q4	$724K	Sell	8,584 -381	-4%	-$30.8K	﹤0.01%	1278
2019 Q3	$670K	Sell	8,965 -1,985	-18%	-$159K	﹤0.01%	1367
2019 Q2	$693K	Buy	10,950 +5,530	+102%	+$280K	﹤0.01%	1364
2019 Q1	$261K	Sell	5,420 -2,415	-31%	-$116K	﹤0.01%	1796
2018 Q4	$262K	Sell	7,835 -10,097	-56%	-$369K	﹤0.01%	1677
2018 Q3	$938K	Sell	17,932 -511	-3%	-$20.3K	0.01%	1153
2018 Q2	$579K	Buy	18,443 +1,900	+11%	+$52.9K	﹤0.01%	1381
2018 Q1	$360K	Buy	+16,543	New	+$356K	﹤0.01%	1590

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

HighTower Advisors's NVCR Position: Q2 2023 in Review

HighTower Advisors sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 4,242 shares — an estimated $256K sold.

HighTower Advisors first reported a position in NVCR in Q1 2018 and held it in 21 quarters. The position peaked at $1.59M in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

HighTower Advisors reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
HighTower Advisors sold 4,242 NovoCure shares in Q2 2023, an estimated $256K.
HighTower Advisors first reported a position in NovoCure in Q1 2018 and held it in 21 quarters.
HighTower Advisors's NovoCure position peaked at $1.59M in Q2 2021.
267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on HighTower Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.